ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

223 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-29

Study Completion Date

2024-09-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension when combined with physical exercise.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

NCT01891513

Hypertension Aging

COMPLETED

Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Trial

NCT02249507

Hypertension

COMPLETED NA

Cardiovascular Effects of Aerobic and Strength Training in Hypertensive Middle-aged Individuals

NCT03282942

Arterial Hypertension

COMPLETED NA

Effect of Exercise on Heart Function in Healthy Elderly People

NCT00804518

Diastolic Dysfunction

COMPLETED NA

Physical Exercise in Hypertension, Randomised Clinical Trial

NCT00218972

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension. Functional status, determined by measures of physical performance, is an important predictor of cardiovascular outcomes in older adults. Seniors with compromised function experience more CV events, have a higher risk of undergoing cardiac surgery and higher risk of CVD-related death than higher-functioning peers. Seniors with hypertension experience accelerated declines in function, and presently physical exercise is the primary strategy for preventing this decline. However, functional responses to exercise are highly variable and appear to be influenced by the type of antihypertensive medication(s) utilized to control blood pressure. Preliminary evidence suggests that, compared to other first-line antihypertensive agents, angiotensin converting enzyme (ACE) inhibitors enhance exercise-derived improvements in functional status among hypertensive seniors. This RCT will test this hypothesis. Sedentary men and women \> 60 years of age with functional limitations and hypertension will be recruited from two sites to participate in a longitudinal intervention study. Participants will be randomly assigned to one of three first-line antihypertensive agents: (1) the ACE inhibitor perindopril, (2) AT1 receptor antagonist losartan, or (3) the thiazide diuretic hydrochlorothiazide. Note: Participants with a documented history of hypersensitivity to ACE inhibitors will be randomized 1:1 to one of the two other study drugs. All participants will also participate in a structured aerobic exercise intervention. The primary aim is to determine if, compared to losartan and HCTZ, perindopril improves self-paced gait speed. The secondary aim is to determine the relative effect of perindopril on a) exercise capacity, b) body mass and composition, and c) circulating indices of cardiovascular risk. This study is expected to differentiate beneficial effects of three FDA-approved antihypertensive medications on an emerging cardiovascular risk factor in a clinically-relevant population. Thus the study has important implications for expeditiously influencing clinical practice guidelines in the prescription of antihypertensive drugs to millions of Americans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Aging Sedentary Lifestyle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perindopril

4 mg qd titrated to 8 mg qd perindopril + aerobic exercise

Group Type ACTIVE_COMPARATOR

Aerobic exercise

Intervention Type BEHAVIORAL

Twice weekly centered based aerobic exercise + 3/week home-based walking

Perindopril

Intervention Type DRUG

4 mg qd titrated to 8 mg qd perindopril

Losartan

50 mg qd titrated to 100 mg qd losartan + aerobic exercise

Group Type ACTIVE_COMPARATOR

Aerobic exercise

Intervention Type BEHAVIORAL

Twice weekly centered based aerobic exercise + 3/week home-based walking

Losartan

Intervention Type DRUG

50 mg qd titrated to 100 qd losartan

HCTZ

12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise

Group Type ACTIVE_COMPARATOR

Aerobic exercise

Intervention Type BEHAVIORAL

Twice weekly centered based aerobic exercise + 3/week home-based walking

HCTZ

Intervention Type DRUG

12.5 mg qd titrated to 25 qd HCTZ

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aerobic exercise

Twice weekly centered based aerobic exercise + 3/week home-based walking

Intervention Type BEHAVIORAL

Perindopril

4 mg qd titrated to 8 mg qd perindopril

Intervention Type DRUG

Losartan

50 mg qd titrated to 100 qd losartan

Intervention Type DRUG

HCTZ

12.5 mg qd titrated to 25 qd HCTZ

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 60 years and older
* Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated
* \> 290 seconds needed to complete long-distance corridor walk test
* Sedentary lifestyle, defined as \<150 min/wk of moderate physical activity
* Willingness to participate in all study procedures, including allowing study team to communicate with primary care physician regarding changes in antihypertensive treatment

Exclusion Criteria

* BP \> 140/90, despite the use of three or more anti-hypertensive drugs
* SBP \> 180 mm Hg or DBP \> 110 mm Hg
* Chronic kidney disease
* Serum creatinine \>2.5 mg/dL in men or \>2.0 mg/dL in women
* Serum potassium outside normal reference range
* Urinary protein \> 1 on dipstick
* Abnormal liver enzymes (AST, ALT, or alkaline phosphatase \> 2.5 times the upper limit of normal)
* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
* Acute myocardial infarction identified by ECG
* Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score \< 24;
* Simultaneous participation in another intervention trial
* Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be randomized among other two interventions)
* Any other condition that would preclude participating based upon judgement of PI or study clinician team

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No